Company Overview of InVitae Corporation
InVitae Corporation, a personal genome management company, provides genetic information to physicians and patients to accelerate the move toward personalized medicine. The company is based in San Francisco, California. As of August 8, 2012, InVitae Corporation operates as a subsidiary of Locus Development Inc.
458 Brannan Street
San Francisco, CA 94107
Founded in 2010
Key Executives for InVitae Corporation
InVitae Corporation does not have any Key Executives recorded.
InVitae Corporation Key Developments
InVitae Corporation Offers Multi-Gene Testing for Hereditary Pancreatic Cancer
Jun 12 14
Invitae Corporation announced that it now offers multi-gene testing for hereditary pancreatic cancer, providing clinicians with a reliable, fast and affordable option for their cancer patients and their families. With results typically available within three weeks, this panel includes an analysis of 17 genes and currently is the most comprehensive panel available. The test is available globally and at a contracted price of $1,500 in the United States. The new Invitae Hereditary Pancreatic Cancer Panel covers the genetic associations most commonly linked to an increased risk of pancreatic cancer and includes the following genes: APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, FANCC, MEN1, MLH1, MSH2, MSH6, PALB2, PALLD, PMS2, STK11, TP53 and VHL. In addition, Invitae offers hereditary pancreatitis genes CFTR and SPINK1, which some providers choose when assessing a patient for hereditary pancreatic cancer. These genes can be included in an Invitae requisition at no additional charge. Additional hereditary cancer panels are available, including testing for BRCA1 and BRCA2, Lynch Syndrome and other colon cancers, and a 29-gene hereditary cancer syndromes panel. In addition to covering more genes than tests available from other providers, Invitae's newest cancer panel provides clinicians and patients with answers more rapidly, at a lower cost.
InVitae Corporation Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-14-2014 05:00 PM
Jan 10 14
InVitae Corporation Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-14-2014 05:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Sean George PhD, President.
InVitae Corporation Responds to Myriad Genetics Lawsuit
Nov 26 13
Invitae Corporation announced that it plans to defend its right to provide naturally occurring genetic information and services to physicians for their cancer patients through its genetic testing services. Invitae has been named a defendant in a lawsuit filed by Myriad Genetics Inc. regarding Invitae's BRCA and MUTYH genetic tests. Invitae disagrees with the allegations of the lawsuit and plans to vigorously defend itself against the lawsuit, which it believes has no merit. Earlier this year, the Supreme Court ruled that naturally occurring DNA and the information it encodes cannot be patented (Assn'n for Molecular Pathology v. Myriad Genetics Inc., 133 S. Ct. 2107 ) and thus ushered in a new era of medicine. This followed on a prior Supreme Court ruling establishing that naturally occurring biological correlations were not patentable subject matter (Mayo Collaborative Servs. v. Prometheus Labs. Inc., 132 S. Ct. 1289 ). The breast cancer community will benefit from these decisions with the introduction of multiple new diagnostic tests to analyze BRCA1 and BRCA2 mutations, increasing the availability and options for patients and physicians. Invitae and its collaborators recently presented results at scientific conferences demonstrating the validity of next generation DNA sequencing technology to accurately identify pathogenic variants in a variety of cancer genes including BRCA1 and 2. Invitae's mission is to reinvent genetic testing by making it more affordable and accessible than ever before. The company's goal is to bring multi-use genetic testing into routine medical practice. Invitae offers full gene sequencing for both BRCA1 and BRCA2 with deletion and duplication analysis to physicians with the ability to upgrade to a larger hereditary cancer syndromes panel of 27 genes - all for just $1,500.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 10, 2013